FDA Puts Innate’s Lymphoma Trials on Partial Hold After Patient Death

[cafead]

via Following a fatality due to the rare blood disease hemophagocytic lymphohistiocytosis, the regulator slapped a partial clinical hold on two studies of Innate Pharma’s investigational therapy lacutamab.

article source